


CXCR7 modulator 2

Chemical Properties

| | |
|-------------------|--|
| CAS No.: | 2227426-37-9 |
| Formula: | C ₂₉ H ₄₂ N ₆ O ₃ |
| Molecular Weight: | 522.68 |
| Appearance: | N/A |
| Storage: | 0-4°C for short term (days to weeks), or -20°C for long term (months). |



Biological Description

| | |
|----------------------------|---|
| Description | CXCR7 modulator 2 is a 7-type C-X-C chemokine receptor (CXCR7) modulator with a Ki of 13 nM. |
| Targets(IC ₅₀) | CXCR7: 13 nM (ki) |
| In vitro | CXCR7 modulator 2 showed strong CXCR7 binding affinity (Ki = 13 nM) and β-arrestin activity (EC ₅₀ = 11 nM). Compared with 11c, CXCR7 modulator 2 also showed improved selectivity in the GPCR panel and showed a higher therapeutic index in the hERG patch clamp assay. CXCR7 modulator 2 exhibited medium to high in vitro turnover in NADPH- supplemented mouse liver microsomes (MLM, 93 μL / min / mg) and hepatocytes (28 μL / min per million cells), which was shown to be more comparable in MDCK Poor passive absorption permeability type II permeability measurement method, and has good water solubility. CXCR7 regulator 2 is rapidly absorbed, with an average maximum plasma concentration (C _{max}) of 682 ng / mL, which appears at 0.25 h (T _{max}). The corresponding average area under the plasma concentration-time curve (AUC) is 740 ng / mL / h. |
| In vivo | The administration of isoproterenol for 9 days will lead to the development of cardiac fibrosis. This is because the amount of collagen deposition detected by Pixirius red staining has increased by about 4 times relative to that of the control group. proven. Treatment with CXCR7 modulator 2 can lead to a statistically significant reduction in cardiac fibrosis, thus demonstrating that CXCR7 modulator 2 has a protective effect on CXCR7 modulation in isoproterenol-induced cardiac injury. |

Solubility Information

| | |
|------------|---|
| Solubility | DMSO: 250 mg/mL (478.30 mM) (< 1 mg/ml refers to the product slightly soluble or insoluble) |
|------------|---|

Preparing Stock Solutions

| | 1mg | 5mg | 10mg |
|-------|----------|----------|-----------|
| 1 mM | 1.913 mL | 9.566 mL | 19.132 mL |
| 5 mM | 0.383 mL | 1.913 mL | 3.826 mL |
| 10 mM | 0.191 mL | 0.957 mL | 1.913 mL |
| 50 mM | 0.038 mL | 0.191 mL | 0.383 mL |

Please select the appropriate solvent to prepare the stock solution, according to the solubility of the product in different solvents. The storage conditions and period of the stock solution: - 80 °C for 6 months; - 20 °C for 1 month. Please use it as soon as possible.

Reference

1. Menhaji-Klotz E, et al. Discovery of a Novel Small-Molecule Modulator of C-X-C Chemokine Receptor Type 7 as a Treatment for Cardiac Fibrosis. J Med Chem. 2018 Apr 26;61(8):3685-3696.

Inhibitors · Natural Compounds · Compound Libraries

This product is for Research Use Only · Not for Human or Veterinary or Therapeutic Use.

Tel:781-999-4286

E-mail:info@targetmol.com

Address:36 Washington Street,Wellesley Hills,MA 02481